Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.26. Hemispherx BioPharma shares last traded at $0.25, with a volume of 149,044 shares.
Hemispherx BioPharma Price Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- What is Insider Trading? What You Can Learn from Insider Trading
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Why is the Ex-Dividend Date Significant to Investors?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
